Related Experiment Video

Updated: Aug 13, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

[Curative antifungal treatment of invasive pulmonary aspergillosis]

E Andrès1, F Courouau, J E Kurtz

  • 1Service de pneumologie, CHU de Strasbourg.

Revue De Pneumologie Clinique
|January 1, 1995
PubMed

Insights

Pulmonary invasive aspergillosis, a serious complication of immunodeficiency, is treated with amphotericin B. Lipid formulations allow higher doses, improving outcomes and renal function, with itraconazole as a second-line therapy.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Pulmonology

Context:

  • Pulmonary invasive aspergillosis is a severe complication in immunocompromised patients, particularly those with prolonged neutropenia.
  • Standard treatment involves intravenous amphotericin B, often limited by renal toxicity.
  • Lipid formulations of amphotericin B offer a potential for dose escalation.

Purpose:

  • To evaluate the efficacy and safety of higher-dose lipid formulations of amphotericin B for pulmonary invasive aspergillosis.
  • To assess the role of itraconazole as a salvage therapy following amphotericin B treatment.

Summary:

  • Lipid-based amphotericin B allows for higher dosing (5 mg/kg/d) compared to conventional formulations (1-1.25 mg/kg/d), potentially improving treatment outcomes.
  • This approach demonstrates good results while preserving renal function.
  • Itraconazole is identified as a viable therapeutic option for patients requiring second-line treatment.

Impact:

  • Higher-dose lipid amphotericin B may represent an improved treatment strategy for pulmonary invasive aspergillosis.
  • This approach could lead to better patient outcomes in this high-risk population.
  • Understanding treatment sequencing, including itraconazole, is crucial for managing this infection.

More Related Videos

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Fungal Phylum Ascomycota01:28

Fungal Phylum Ascomycota

Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...